dc.creator | Majem, M. | es |
dc.creator | Manzano, J. L. | es |
dc.creator | Marquez-Rodas, I. | es |
dc.creator | Mujika, K. | es |
dc.creator | Muñoz-Couselo, E. | es |
dc.creator | Pérez-Ruiz, E. | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Espinosa, E. | es |
dc.creator | Gonzalez-Cao, M. | es |
dc.creator | Berrocal, A. | es |
dc.date.accessioned | 2022-10-10T13:32:37Z | |
dc.date.available | 2022-10-10T13:32:37Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Majem, M., Manzano, J.L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E.,...,Berrocal, A. (2021). SEOM clinical guideline for the management of cutaneous melanoma (2020). Clinical and Translational Oncology, 23 (5), 948-960. https://doi.org/10.1007/s12094-020-02539-9. | |
dc.identifier.issn | 1699-048X | es |
dc.identifier.uri | https://hdl.handle.net/11441/137761 | |
dc.description.abstract | Melanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology
(SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of
these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage≥III.
Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immuno‑
therapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with
immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate
consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to
receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. | es |
dc.format | application/pdf | es |
dc.format.extent | 13 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer Nature | es |
dc.relation.ispartof | Clinical and Translational Oncology, 23 (5), 948-960. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Melanoma | es |
dc.subject | Adjuvant treatment metastatic treatment | es |
dc.subject | Staging | es |
dc.title | SEOM clinical guideline for the management of cutaneous melanoma (2020) | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s12094-020-02539-9 | es |
dc.identifier.doi | 10.1007/s12094-020-02539-9 | es |
dc.journaltitle | Clinical and Translational Oncology | es |
dc.publication.volumen | 23 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 948 | es |
dc.publication.endPage | 960 | es |